Home
About
Overview
Sharing Data
ORCID
Help
History (32)
Crohn's disease: step up or top down therapy.
A randomized, placebo-controlled, phase II study of tetomilast in active ulcerative colitis.
Adalimumab sustains steroid-free remission after 3 years of therapy for Crohn's disease.
Protection from primary sclerosing cholangitis: smoke trails of just coattails?
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
See All 32 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002 May 04; 359(9317):1541-9.
View in:
PubMed
subject areas
Adult
Aged
Analysis of Variance
Antibodies, Monoclonal
Chi-Square Distribution
Crohn Disease
Cross-Over Studies
Double-Blind Method
Female
Gastrointestinal Agents
Humans
Infliximab
Infusions, Intravenous
Male
Middle Aged
Remission Induction
Treatment Outcome
authors with profiles
Stephen B. Hanauer